Keyphrases
African American
100%
Heart Failure Trials
100%
Hydralazine
100%
Isosorbide Dinitrate
100%
Heart Failure Hospitalization
54%
Event-free Survival
27%
Quality of Life
18%
Survival Time
18%
Fixed-dose Combination
18%
Treatment Interaction
18%
Composite Score
18%
All-male
18%
All-cause Mortality
9%
Patients with Heart Failure
9%
Quality of Life Improvement
9%
Quality of Life Assessment
9%
Black Men
9%
Systolic Blood Pressure
9%
Baseline Characteristics
9%
Reduced Mortality
9%
Placebo Treatment
9%
Hemoglobin Level
9%
Neurohormonal Blockade
9%
Creatinine Level
9%
Renal Insufficiency
9%
Heart Failure Outcomes
9%
Time Since Death
9%
Low Hemoglobin
9%
Composite Events
9%
Diabetes Prevalence
9%
High Body Mass Index
9%
Heart Failure Events
9%
Mortality Benefit
9%
Pharmacology, Toxicology and Pharmaceutical Science
Hydralazine
100%
Congestive Heart Failure
100%
Isosorbide Dinitrate
100%
Event Free Survival
27%
Cohort Study
18%
Survival Time
18%
Placebo
9%
All Cause Mortality
9%
Prevalence
9%
Creatinine
9%
Kidney Failure
9%
Nursing and Health Professions
Congestive Heart Failure
100%
Isosorbide Dinitrate/Hydralazine
100%
Quality of Life
36%
Event Free Survival
27%
Cohort Analysis
18%
Survival Time
18%
Kidney Failure
9%
Body Mass
9%
Placebo
9%
Systolic Blood Pressure
9%
Prevalence
9%
Creatinine
9%
All Cause Mortality
9%